文献速递造血干细胞移植与细胞治疗淋巴瘤浆细胞疾病

电子衰弱指数与接受CAR-T治疗的老年人结局相关

An Electronic Frailty Index Is Associated with Outcomes in Older Adults Receiving CAR-T Therapy.
PubMed 文献 · Blood Adv · 2026-10-02

本研究回顾性分析了260例接受商业CAR-T治疗的≥65岁多发性骨髓瘤和B细胞非霍奇金淋巴瘤患者,计算电子衰弱指数(eFI)并评估其与总生存(OS)、无事件生存(EFS)、毒性及30天内院外存活天数的关联。多因素分析显示,非常衰弱患者OS和EFS显著较差,衰弱和非常衰弱患者3级及以上毒性风险更高且院外存活天数更少。eFI可作为自动化的CAR-T风险分层工具。

要点

  • eFI可识别衰弱和非常衰弱患者,其3级及以上CRS/ICANS风险更高。
  • 非常衰弱患者OS和EFS显著较差,需特别关注。
  • eFI有潜力作为自动化的CAR-T风险分层工具。

核心结论

  • eFI可识别衰弱和非常衰弱患者,其3级及以上CRS/ICANS风险更高且医疗资源利用增加。
  • 非常衰弱患者尤其高危,OS和EFS较差。

研究设计与样本

  • 回顾性分析260例年龄≥65岁接受商业CAR-T治疗的多发性骨髓瘤和B细胞非霍奇金淋巴瘤患者,中位年龄73岁(范围65-91)。
  • 计算电子衰弱指数(eFI),按<0.1=健壮、0.1-0.2=前衰弱、0.2-0.3=衰弱、>0.3=非常衰弱分组。

主要发现

  • 260例中,10%健壮,25%前衰弱,28%衰弱,37%非常衰弱。
  • 多因素分析中,衰弱与OS无关(HR 1.22,p=0.45),与EFS无关(HR=1.39,p=0.14)。
  • 非常衰弱患者OS显著较差(HR=1.64,p<0.05),EFS显著较差(HR=2.02,p<0.01)。
  • 衰弱和非常衰弱患者3级及以上毒性风险更高(OR=3.28,p<0.05;OR=4.84,p<0.01)。
  • 衰弱和非常衰弱患者30天内院外存活天数更少(β=-2.37,p=0.03;β=-3.79,p<0.01)。

关键数值与推荐

  • eFI分级标准:<0.1=健壮,0.1-0.2=前衰弱,0.2-0.3=衰弱,>0.3=非常衰弱。

临床怎么用

  • eFI可自动化计算,用于CAR-T治疗前风险分层,识别高危衰弱患者。
  • 对衰弱和非常衰弱患者,应加强毒性监测和资源规划。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Predicting outcomes for older adults undergoing Chimeric Antigen Receptor T-cell (CAR-T) therapy is critical. Frailty is associated with poor outcomes, but can be difficult to measure in clinical practice. We retrospectively analyzed patients age ≥65 years receiving commercial CAR-T at Mass General Brigham for multiple myeloma and B-cell non-Hodgkin lymphoma. We calculated an electronic frailty index (eFI), a validated, automated frailty score (<0.1=robust, 0.1-0.2=pre-frail, 0.2-0.3=frail, and >0.3=very frail). We evaluated associations of eFI (robust/prefrail vs frail vs very frail) with overall survival (OS), event-free (death, progression, or new treatment) survival (EFS), toxicity (cytokine release syndrome (CRS) and/or immune effector cell-associated neurotoxicity syndrome (ICANS)), and days alive and out of hospital in the first 30 days (DAOH) using regression models controlling for confounders. Among 260 patients (median age: 73 years [range 65-91]), 10% were robust, 25% prefrail, 28% frail, and 37% very frail. In multivariable analyses, being frail was not associated with OS (hazard ratio [HR] 1.22, p=0.45) or EFS (HR=1.39, p=0.14), but very frail patients had significantly worse OS (HR=1.64, p<0.05) and EFS (HR=2.02, p<0.01). Both frail and very frail patients, respectively, had higher odds of grade 3+ toxicity (odds ratio [OR]=3.28, p<0.05; OR=4.84, p<0.01) and fewer DAOH (β= -2.37, p = 0.03; β= -3.79, p<0.01). The eFI identifies frail and very frail patients with higher risk for grade 3+ CRS/ICANS and increased healthcare utilization. Very frail patients are especially high-risk with poor OS and EFS. The eFI holds promise as an automated CAR-T risk-stratification tool.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Enns JP, Korst MR, Horick N, et al. An Electronic Frailty Index Is Associated with Outcomes in Older Adults Receiving CAR-T Therapy. Blood Adv. 2026. PMID: 42826706. doi:10.1182/bloodadvances.2026021361

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。